BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 15746068)

  • 41. A partially agonistic peptide acts as a selective inducer of apoptosis in CD8+ CTLs.
    Wei CH; Beeson C; Masucci MG; Levitsky V
    J Immunol; 1999 Sep; 163(5):2601-9. PubMed ID: 10452999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer.
    Perambakam S; Xue BH; Sosman JA; Peace DJ
    Cancer Immunol Immunother; 2002 Jul; 51(5):263-70. PubMed ID: 12070713
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dendritic cells prolong tumor-specific T-cell survival and effector function after interaction with tumor targets.
    Mailliard RB; Lotze MT
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):980s-988s. PubMed ID: 11300500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A method to increase tetramer staining efficiency of CD8+ T cells with MHC-peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment.
    Tsai SL; Lee TH; Chien RN; Liao SK; Lin CL; Kuo GC; Liaw YF
    J Immunol Methods; 2004 Feb; 285(1):71-87. PubMed ID: 14871536
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.
    Valmori D; Scheibenbogen C; Dutoit V; Nagorsen D; Asemissen AM; Rubio-Godoy V; Rimoldi D; Guillaume P; Romero P; Schadendorf D; Lipp M; Dietrich PY; Thiel E; Cerottini JC; Liénard D; Keilholz U
    Cancer Res; 2002 Mar; 62(6):1743-50. PubMed ID: 11912149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2.
    Darrow TL; Abdel-Wahab Z; Quinn-Allen MA; Seigler HF
    Cell Immunol; 1996 Aug; 172(1):52-9. PubMed ID: 8806806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma.
    Murray JL; Gillogly M; Kawano K; Efferson CL; Lee JE; Ross M; Wang X; Ferrone S; Ioannides CG
    Cancer Res; 2004 Aug; 64(15):5481-8. PubMed ID: 15289358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes.
    Azuma T; Otsuki T; Kuzushima K; Froelich CJ; Fujita S; Yasukawa M
    Clin Cancer Res; 2004 Nov; 10(21):7402-12. PubMed ID: 15534117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
    Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
    Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Response of established human breast tumors to vaccination with mammaglobin-A cDNA.
    Narayanan K; Jaramillo A; Benshoff ND; Campbell LG; Fleming TP; Dietz JR; Mohanakumar T
    J Natl Cancer Inst; 2004 Sep; 96(18):1388-96. PubMed ID: 15367572
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.
    Valmori D; Dutoit V; Rubio-Godoy V; Chambaz C; Liénard D; Guillaume P; Romero P; Cerottini JC; Rimoldi D
    Cancer Res; 2001 Jan; 61(2):509-12. PubMed ID: 11212242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells.
    Glazyrin AL; Kan-Mitchell J; Mitchell ML
    Cancer Immunol Immunother; 2003 Mar; 52(3):171-8. PubMed ID: 12649746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Prediction synthesis and identification of HLA-A2-restricted cytotoxic T lymphocyte epitopes of the tumor antigen MAGE-n].
    Dong HL; Sui YF; Ye J; Li ZS; Qu P; Zhang XM; Chen GS; Lu SY
    Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(12):1080-3. PubMed ID: 12899783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytokine combinations for induction of antigen-specific cytolytic T lymphocytes from peripheral blood lymphocytes.
    Tsujitani S; Nakashima M; Watanabe T; Kaibara N; Koprowski H; Steplewski Z
    Anticancer Res; 1995; 15(3):655-60. PubMed ID: 7645938
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
    Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Takao Y; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
    Prostate; 2005 Feb; 62(3):233-42. PubMed ID: 15389794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs.
    Fujiwara H; Sconocchia G; Melenhorst J; Eniafe R; Nakamura R; Hensel N; Barrett AJ
    Bone Marrow Transplant; 2003 Aug; 32(4):371-8. PubMed ID: 12900773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peptide affinity and concentration affect the sensitivity of M3-restricted CTLs induced in vitro.
    Byers DE; Lindahl KF
    J Immunol; 1999 Sep; 163(6):3022-8. PubMed ID: 10477565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life.
    Rubio-Godoy V; Dutoit V; Rimoldi D; Lienard D; Lejeune F; Speiser D; Guillaume P; Cerottini JC; Romero P; Valmori D
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10302-7. PubMed ID: 11517329
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE; Pilarski LM; Allen TM
    Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.
    Latouche JB; Sadelain M
    Nat Biotechnol; 2000 Apr; 18(4):405-9. PubMed ID: 10748520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.